GeneGo, Inc. Awarded Phase II Toxicogenomics Grant By National Institute of Environmental Health Sciences

ST. JOSEPH, Mich., May 15 /PRNewswire/ -- GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that they have received a $750,000 Phase II SBIR grant from National Institute of Environmental Health Sciences (NIEHS) for the development of functional descriptors for gene expression response to drugs and toxins as part of their MetaTox product line.

"Toxicogenomics is a mature OMICs field, with a huge amount of drug response data accumulated in industry and the public domain," said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. "However, one third of compounds are still withdrawn from clinical trials due to human toxicity unseen in pre-clinical toxicogenomics profiling. We see the problem not in the approach itself, but in data interpretation techniques, heavily focused on statistics-derived gene signatures. In this grant, we propose to develop a new concept of functional descriptors and network models for toxicogenomics data analysis, and we are happy that NIEHS share this vision."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.3(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.2(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at www.genego.com

MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM) and MetaMiner(TM), 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.

CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,Inc., +1-858-756-7996, julie@genego.com

Web site: http://www.genego.com/